ACVR2A and anemia (phenotype): Additional clinical trials evaluating other promising novel agents and studies reporting real-world evidence are necessary to validate the therapeutic potential of novel ACVR1 inhibitors, ACVR2 ligand traps, or other agents to treat anemia in MF and pave the way to broader clinical applications and paradigm changes in the treatment of MF.